Form 4: Forsyth Acquires 149,564 Shares of Inhibrx Biosciences Following Distribution from Inhibrx, Inc.

Director Douglas Forsyth acquires 149,564 shares of Inhibrx Biosciences due to the distribution of shares from Inhibrx, Inc. and receives a stock option for 30,000 shares.

Summary

• Douglas Forsyth, a director of Inhibrx Biosciences, Inc., acquired 149,564 shares of common stock on May 29, 2024.
• This acquisition resulted from the distribution by Inhibrx, Inc. of 92% of Inhibrx Biosciences' common stock to Inhibrx, Inc. shareholders.
• The distribution ratio was one share of Inhibrx Biosciences for every four shares of Inhibrx, Inc. held on the record date of May 17, 2024.
• Forsyth also received a stock option to purchase 30,000 shares of Inhibrx Biosciences common stock at an exercise price of $15.86 on May 30, 2024.
• The stock option will be fully exercisable on May 30, 2025, contingent upon Forsyth's continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports transactions related to a corporate restructuring and stock option grant, without expressing explicit positive or negative views on the company's prospects.

Positives

• Forsyth's increased stake in Inhibrx Biosciences could signal confidence in the company's future prospects.
• The granting of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service and potential value creation.

Industry Context

This announcement follows the merger of Inhibrx, Inc. with a subsidiary of Sanofi, resulting in the distribution of Inhibrx Biosciences shares. This type of corporate restructuring and distribution is not uncommon in the biotech industry as companies look to streamline operations or spin off specific assets.

Comparison to Industry Standards

• Stock option grants are a common practice in the biotechnology industry to incentivize key personnel, such as directors, and align their interests with those of shareholders.
• The size and terms of the stock option grant are within the typical range for similar companies in the biotech sector.
• Comparable companies such as argenx SE and BioNTech SE also use stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• Shareholders of Inhibrx, Inc. received shares of Inhibrx Biosciences, impacting their investment portfolio.
• The stock option grant incentivizes the director to contribute to the company's success, potentially benefiting all stakeholders.

Key Dates